Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, Onuma Y, Simonton C, Zhang Z, Stone GW. 2-year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390(10096):760–72.

Article  CAS  PubMed  Google Scholar 

Chevalier B, Cequier A, Dudek D, Haude M, Carrie D, Sabate M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iniguez A, Onuma Y, Serruys PW. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention. 2018;13(13):1561–4.

Article  PubMed  Google Scholar 

Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrie D, Sabate M, Windecker S, Rapoza RR, West NEJ, Reith S, de Sousa Almeida M, Campo G, Iniguez-Romo A, Serruys PW. Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial. EuroIntervention. 2020;16(11):e938–41.

Article  PubMed  Google Scholar 

Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43–54.

Article  CAS  PubMed  Google Scholar 

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, E.S.C.S.D. Group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.

Article  PubMed  Google Scholar 

Gomez-Lara J, Ortega-Paz L, Brugaletta S, Cuesta J, Romani S, Serra A, Salinas P, Garcia Del Blanco B, Goicolea J, Hernandez-Antolin R, Antuna P, Romaguera R, Regueiro A, Rivero F, Cequier A, Alfonso F, Gomez-Hospital JA, Sabate M. Collaborators, Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention. 2020;16(11):e913–21.

Article  PubMed  Google Scholar 

Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Lim ST, Escaned J, Onuma Y, Garcia-Garcia HM, Waksman R. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J. 2016;37(35):2701–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kochman J, Koltowski L, Tomaniak M, Jakala J, Proniewska K, Legutko J, Roleder T, Piertrasik A, Rdzanek A, Kochman W, Brugaletta S, Opolski G, Regar E. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation absorb bioresorbable vascular scaffold. EuroIntervention. 2018;13(18):e2201–9.

Article  PubMed  Google Scholar 

Leibundgut G. A novel, radiopaque, bioresorbable tyrosine-derived polymer for cardiovascular scaffolds, cardiac interventions today, vol., no 2018, p. European Featured Technology. 2018. Available online: https://citoday.com/articles/2018-july-aug/a-novel-radiopaque-bioresorbable-tyrosine-derived-polymer-for-cardiovascular-scaffolds?c4src=archive:feed. Accessed 29 Feb 2020.

Lutz M, Anderson J, Abizaid A, et al. TCT CONNECT-270 FANTOM II Trial: Safety and performance study of the fantom sirolimus-eluting bioresorbable coronary scaffold—first report: 4-year clinical outcomes. J Am Coll Cardiol. 2020;76(17 Supplement S):B118.

Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013;9(4):501–4.

Article  PubMed  Google Scholar 

Koltowski L, Tomaniak M, Ochijewicz D, Maksym J, Roleder T, Zaleska M, Proniewska K, Opolski G, Kochman J. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study. Catheter Cardiovasc Interv. 2020;96(1):E1–7.

Article  PubMed  Google Scholar 

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, C Academic research. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.

Article  PubMed  Google Scholar 

Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897–910.

Article  CAS  PubMed  Google Scholar 

Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation. 2004;109(7):881–6.

Article  PubMed  Google Scholar 

Scalone G, Brugaletta S, Gomez-Monterrosas O, Otsuki S, Sabate M. ST-segment elevation myocardial infarction - ideal scenario for bioresorbable vascular scaffold implantation? Circ J. 2015;79(2):263–70.

Article  PubMed  Google Scholar 

Sabate M, Windecker S, Iniguez A, Okkels-Jensen L, Cequier A, Brugaletta S, Hofma SH, Raber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G, Sotomi Y, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229–40.

Article  CAS  PubMed  Google Scholar 

Abizaid A, Carrie D, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Weng SC, Costa RA, Anderson J, Stone GW, Investigators FIC. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: the FANTOM II study. JACC Cardiovasc Interv. 2017;10(18):1832–8.

Article  PubMed  Google Scholar 

Simonsen JK, Holck EN, Carrie D, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Daemen J, Dijkstra J, Fox Maule C, Neghabat O, Lassen JF, Anderson J, Christiansen EH, Abizaid A, Holm NR. Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study. Open Heart. 2019;6(1):e000941.

Article  PubMed  PubMed Central  Google Scholar 

Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, Katagiri Y, Modolo R, Tenekecioglu E, Morel MA, Garg S, Wykrzykowska J, Piek JJ, Sabate M, Morice MC, Chevalier B, Windecker S, Onuma Y. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018;39(36):3381–9.

Article  PubMed  Google Scholar 

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109(18):2168–71.

Article  CAS  PubMed  Google Scholar 

Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38–42.

Article  CAS  PubMed  Google Scholar 

Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE, Investigators EI. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114(8):798–806.

Article  CAS  PubMed  Google Scholar 

Sato T, Jose J, El-Mawardy M, Sulimov DS, Tölg R, Richardt G, Abdel-Wahab M. Relationship between peri-strut low intensity areas and vascular healing response after everolimus-eluting bioresorbable scaffold implantation: an optical coherence tomography study. J Cardiol. 2017;69(4):606–12.

Article  PubMed  Google Scholar 

Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94(10):1362–7.

Article  CAS  PubMed  PubMed Central  Google Scholar